Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aceclidine is a direct-acting cholinergic small molecule used as an ophthalmic miotic. It functions primarily as a muscarinic receptor agonist on the iris sphincter and ciliary muscle, producing pupillary constriction that can improve near vision through a pinhole effect in presbyopia. Historically it has also been studied as an antiglaucoma miotic and was noted in older literature to induce less accommodative spasm than pilocarpine in some patients. More recently, LENZ Therapeutics developed aceclidine ophthalmic solution 1.44% as the monotherapy product LNZ100, which was commercialized in the United States as VIZZ for presbyopia; the same active ingredient has also been studied in combination with brimonidine as LNZ101 for presbyopia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclidine.